Associations of Postdischarge Follow‐Up With Acute Care and Mortality in Lupus: A Medicare Cohort Study

Abstract

ObjectivePatients with systemic lupus erythematosus experience the sixth highest rate of 30‐day readmissions among chronic diseases. Timely postdischarge follow‐up is a marker of ambulatory care quality that can reduce readmissions in other chronic conditions. Our objective was to test the hypotheses that 1) beneficiaries from populations experiencing health disparities, including patients from disadvantaged neighborhoods, will have lower odds of completed follow‐up, and that 2) follow‐up will predict longer time without acute care use (readmission, observation stay, or emergency department visit) or mortality.MethodsThis observational cohort study included hospitalizations in January–November 2014 from a 20% random sample of Medicare adults. Included hospitalizations had a lupus code, discharge to home without hospice, and continuous Medicare A/B coverage for 1 year before and 1 month after hospitalization. Timely follow‐up included visits with primary care or rheumatology within 30 days. Thirty‐day survival outcomes were acute care use and mortality adjusted for sociodemographic information and comorbidities.ResultsOver one‐third (35%) of lupus hospitalizations lacked 30‐day follow‐up. Younger age, living in disadvantaged neighborhoods, and rurality were associated with lower odds of follow‐up. Follow‐up was not associated with subsequent acute care or mortality in beneficiaries age <65 years. In contrast, follow‐up was associated with a 27% higher hazard for acute care use (adjusted hazard ratio [HR] 1.27 [95% confidence interval (95% CI) 1.09–1.47]) and 65% lower mortality (adjusted HR 0.35 [95% CI 0.19–0.67]) among beneficiaries age ≥65 years.ConclusionOne‐third of lupus hospitalizations lacked follow‐up, with significant disparities in rural and disadvantaged neighborhoods. Follow‐up was associated with increased acute care, but 65% lower mortality in older systemic lupus erythematosus patients. Further development of lupus‐specific postdischarge strategies is needed.image